https://dnadamageinhibitors.co....m/hereditary-evidenc
In this existing study, we developed and tested an injectable, slow-release, uniform, and optimally filled alginate nanoformulation of CCL21 as a means to give prolonged intratumoral therapy. The alginate-nanoformulated CCL21, when injected intratumorally into mice bearing neuroblastoma lesions, considerably prolonged success and reduced the tumor development price contrasted to CCL21 alone, empty nanoparticle
Like
Comment
Share
